Spectral AI began manufacturing its first 30 DeepView AI systems.
The company requested a $2,750 per patient Medicare reimbursement add-on payment.
Full-year 2026 research revenue guidance was updated to approximately $13 million.
On its third-quarter 2026 earnings call, held on Nov. 10, 2026, Spectral AI (NASDAQ:MDAI) announced progress in transitioning from a research organization into a commercial medical technology enterprise. The shift from government-funded research toward recurring commercial software revenue could shape the company's long-term results. Three things management said stand out.
Management launched production of its initial 30 DeepView AI units, an artificial intelligence wound assessment platform, to support government-backed hospital placements. This deployment aims to build the clinical foundation for commercial sales targeted in 2026.
To that end, during this quarter, we began manufacturing the first 30 DeepView AI systems for BARDA supported deployments at US burn centers.
-- Vincent Stanley Capone, Chief Executive Officer
Spectral AI applied for a New Technology Add-on Payment, or NTAP, through the Centers for Medicare and Medicaid Services, known as CMS. Approval would provide hospitals with an additional $2,750 per patient in Medicare reimbursement, which could lower economic barriers to adoption for health systems.
Early in the third quarter, we submitted a new technology add on payment or NTAP application to the Centers for Medicare and Medicaid Services for our Deep View system.
-- Vincent Stanley Capone, Chief Executive Officer
The company structures commercial agreements as minimum three-year terms pairing device access with recurring software subscriptions. Management expects commercial sales to deliver higher margins than its development work as the installed base expands.
Our commercial model pairs device purchases or leases with recurring software and service revenue under agreements with a minimum 3-year term...
-- David McGuire, Chief Financial Officer
Routine burn care represents the primary commercial expansion target beyond mass-casualty preparedness. Clinical validation and hospital procurement progress drive management's commercial strategy.
While preparedness remains an important component of our strategy, we believe the much greater opportunity is to make this technology available as part of the clinical protocol for everyday burn care.
-- Vincent Stanley Capone, Chief Executive Officer
Long-term growth depends on expanding the U.S. hospital footprint, securing higher reimbursement, and building recurring subscription revenue.
Our focus is on delivering for our initial customers, learning from each deployment, and establishing the process that can support a broader adoption across the United States.
-- Vincent Stanley Capone, Chief Executive Officer
Before you buy stock in Spectral Ai, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Spectral Ai wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 21, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.